RayKnowChina Research Map
Shortlist0

Shantou University Medical College

汕头大学医学院

ShantouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.3%Leads under 1 in 100 of China's research papers on NPC

Led 8 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 112025
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseSide effects & quality of life

Hospitals counted here

  1. Shantou University Medical College hospitals8

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomi2021Cancer medicineRCTFree full text
  2. Nasal irrigation reduces radiation-induced rhinosinusitis in nasopharyngeal carcinoma treated with volumetric modulated arc therapy.2026Journal of stomatology, oral and maxillofacial surgery
  3. Comparing Flaps and Artificial Dermis for Skull Base Osteoradionecrosis Repair in Nasopharyngeal Carcinoma.2025The Laryngoscope
  4. Autoantibody Signatures as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.2021Archives of medical research
  5. Adiponectin Receptor 1-vascular endothelial growth factor axis mediates resistance to epidermal growth factor receptor-targeted therapy in nasopharyngeal carcinoma.2026Anti-cancer drugs
Trials on ClinicalTrials.gov6
  1. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  2. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  3. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  4. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  5. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Study sitePhase 2Start 2024-06
  6. Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal CancerCompletedNCT05564286Lead sponsorPhase 3Start 2021-07

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
2.3%Leads about 1 in 44 of China's research papers on ESCC ▼ from 3.6%

Led 66 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
2
Research papers it led
66
Trials it led
3
Share of China's trials
0.5%
Share of the world's papers
1.5%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025
ThemesMolecular markers & genomicsImaging & AINeoadjuvant & combined treatment

Hospitals counted here

  1. Shantou University Medical College hospitals66

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin-bundling activity and tumor metastasis in esophageal squamous cell carcinoma.2022Cancer communications (London, England)Free full text
  2. P300/CBP-associated factor (PCAF)-mediated acetylation of Fascin at lysine 471 inhibits its actin-bundling activity and tumor metastasis in esophageal cancer.2021Cancer communications (London, England)Free full text
  3. Increased IgG4 expression within tertiary lymphoid structures of esophageal cancer and implications for prognosis.2025Frontiers in immunologyFree full text
  4. Prognostic Value of Deep Learning-Extracted Tumor-Infiltrating Lymphocytes in Esophageal Cancer: A Multicenter Retrospective Cohort Study.2025Cancer medicineFree full text
  5. Machine learning technique-based four-autoantibody test for early detection of esophageal squamous cell carcinoma: a multicenter, retrospective study with a nested case-control study.2025BMC medicineFree full text
Trials on ClinicalTrials.gov6
  1. Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07339488Lead sponsorPhase 2Start 2025-12
  2. Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell CarcinomaRecruitingNCT05984342Lead sponsorPhase 1Start 2023-08
  3. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  5. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Study sitePhase 2Start 2024-10
  6. Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal CancerCompletedNCT01670409Lead sponsorPhase 2Start 2012-08

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.2%Leads under 1 in 100 of China's research papers on HCC

Led 25 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
25
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsHepatitis B & cirrhosis

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shantou University Medical College hospitals25

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.3%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 26 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
26
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsImaging & AI

Hospitals counted here

  1. Shantou University Medical College hospitals26

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study.2025International immunopharmacology
  2. Combined detection of serum EFNA1 and MMP13 as diagnostic biomarker for gastric cancer.2024Scientific reportsFree full text
  3. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.2023BMC gastroenterologyFree full text
  4. Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer.2021BioengineeredFree full text
  5. Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.2021Bioscience reportsFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  3. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  4. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  5. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  6. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.4%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 9 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shantou University Medical College hospitals9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.1%Leads under 1 in 100 of China's research papers on Myeloma New since 2021

Led 2 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.02%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesDrug combinations

Hospitals counted here

  1. Shantou University Medical College hospitals Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
1.0%Leads under 1 in 100 of China's research papers on Beta thalassaemia New since 2021

Led 3 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Shantou University Medical College hospitals3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
0.0%Leads none of China's research papers on Biliary atresia

Led 0 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.2%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 2 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Shantou University Medical College hospitals2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.3%Leads under 1 in 100 of China's research papers on IgA nephropathy New since 2021

Led 2 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Shantou University Medical College hospitals2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov